0

Close
 
Upcoming Allied Market Research
2023
Estrogen Receptor-positive Breast Cancer Pipeline Market

Estrogen Receptor-Positive Breast Cancer Pipeline Market

by Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3), by Route of Administration (Oral, Intravenous, Subcutaneous), by Target (Phosphatidylinositol-3-Kinase, Cyclin-Dependent Kinase, Histone Deacetylase, Others) and by End User (Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13353
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Estrogen Receptor-positive Breast Cancer Pipeline Market

Request Now !

Estrogen receptor positive (ER +) breast cancer is the most common type of breast cancer diagnosed. It refers to cancer cells that have estrogen-binding receptors on their surface. Breast cancer is said to have a positive estrogen receptor (ER +). Breast cancer is a syndrome that affects the breast tissues. Breast cells grow out of control, forming bumps that can be felt or seen on x-rays. Selective estrogen receptor modulators such as tamoxifen is prescribed to reduce risk of endometrial cancer. Moreover, surgery such as mastectomy, medications such asletrozole, radiation, and chemotherapy are used in treatment of estrogen receptor positive breast cancer.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the estrogen receptor positive breast cancer pipeline market.

Top Impacting Factors

  • Increase in cases of genetic mutation disorder, rise in prevalence of breast cancer, surge in demand for minimally invasive cancer treatments, adoption of western lifestyle, rise in consumption of tobacco, and increase in awareness regarding treatment & diagnosis of cancer are the factors that drive the growth of market.
  • In addition, surge in unhealthy & sedentary lifestyle in developing countries, government initiative to build advance diagnosis centers, R & D activities to improve efficacy of breast cancer treatment therapies, launch of novel drug therapies, and emerging modern technology in developing countries are some factors that drive the growth of market.
  • However, high cost of breast cancer treatment hinder the growth of market.
  • Contrarily, increase in support by government to spread awareness campaign regarding breast cancer treatment & diagnosis is expected to offer lucrative opportunities in market.

Market Trends

New Product Launches to Flourish the Market

In 2020, Eisai Co. Ltd. announced launch of series of products, LENVIMA, HALAVEN, and H3B-6545. This therapeutic products help in treatment of ER positive breast cancer and HER2 negative breast cancer.

In 2019, Mylan announced launch of its generic version of Faslodex injection in U.S. This product is used in treatment of hormone receptor positive such as estrogen receptor positive breast cancer.

Key Benefits of the Report

  • This study presents the analytical depiction of estrogen receptor positive breast cancer pipeline market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Estrogen Receptor Positive Breast Cancer Pipeline Market Report

  • Which are the leading players active in the estrogen receptor positive breast cancer pipeline market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "estrogen receptor positive breast cancer pipeline "?
  • What is "estrogen receptor positive breast cancer pipeline" market prediction in the future?
  • Who are the leading global players in the "estrogen receptor positive breast cancer pipeline" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "estrogen receptor positive breast cancer pipeline" market report?

 Estrogen Receptor-Positive Breast Cancer Pipeline Market Report Highlights

Aspects Details
By Phase
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
By Target
  • Phosphatidylinositol-3-Kinase
  • Cyclin-Dependent Kinase
  • Histone Deacetylase
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Key Market Players AstraZeneca, GlaxoSmithKline plc, Genentech, Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Teva Pharmaceuticals USA, Inc., Alvogen., Apotex Corp., Breckenridge Pharmaceutical, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY PHASE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Phase

    • 4.2. Pre-Clinical

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Phase 1

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Phase 2

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Phase 3

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Intravenous

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Subcutaneous

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY TARGET

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Target

    • 6.2. Phosphatidylinositol-3-Kinase

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Cyclin-Dependent Kinase

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Histone Deacetylase

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Ambulatory Surgical Centers

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Others

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Phase

      • 8.2.3. Market Size and Forecast, By Route Of Administration

      • 8.2.4. Market Size and Forecast, By Target

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.2.7.1. Market Size and Forecast, By Phase
        • 8.2.7.2. Market Size and Forecast, By Route Of Administration
        • 8.2.7.3. Market Size and Forecast, By Target
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.2.8.1. Market Size and Forecast, By Phase
        • 8.2.8.2. Market Size and Forecast, By Route Of Administration
        • 8.2.8.3. Market Size and Forecast, By Target
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.2.9.1. Market Size and Forecast, By Phase
        • 8.2.9.2. Market Size and Forecast, By Route Of Administration
        • 8.2.9.3. Market Size and Forecast, By Target
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Phase

      • 8.3.3. Market Size and Forecast, By Route Of Administration

      • 8.3.4. Market Size and Forecast, By Target

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.3.7.1. Market Size and Forecast, By Phase
        • 8.3.7.2. Market Size and Forecast, By Route Of Administration
        • 8.3.7.3. Market Size and Forecast, By Target
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.3.8.1. Market Size and Forecast, By Phase
        • 8.3.8.2. Market Size and Forecast, By Route Of Administration
        • 8.3.8.3. Market Size and Forecast, By Target
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.3.9.1. Market Size and Forecast, By Phase
        • 8.3.9.2. Market Size and Forecast, By Route Of Administration
        • 8.3.9.3. Market Size and Forecast, By Target
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.3.10.1. Market Size and Forecast, By Phase
        • 8.3.10.2. Market Size and Forecast, By Route Of Administration
        • 8.3.10.3. Market Size and Forecast, By Target
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.3.11.1. Market Size and Forecast, By Phase
        • 8.3.11.2. Market Size and Forecast, By Route Of Administration
        • 8.3.11.3. Market Size and Forecast, By Target
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.3.12.1. Market Size and Forecast, By Phase
        • 8.3.12.2. Market Size and Forecast, By Route Of Administration
        • 8.3.12.3. Market Size and Forecast, By Target
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.3.13.1. Market Size and Forecast, By Phase
        • 8.3.13.2. Market Size and Forecast, By Route Of Administration
        • 8.3.13.3. Market Size and Forecast, By Target
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Phase

      • 8.4.3. Market Size and Forecast, By Route Of Administration

      • 8.4.4. Market Size and Forecast, By Target

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.7.1. Market Size and Forecast, By Phase
        • 8.4.7.2. Market Size and Forecast, By Route Of Administration
        • 8.4.7.3. Market Size and Forecast, By Target
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.8.1. Market Size and Forecast, By Phase
        • 8.4.8.2. Market Size and Forecast, By Route Of Administration
        • 8.4.8.3. Market Size and Forecast, By Target
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.9.1. Market Size and Forecast, By Phase
        • 8.4.9.2. Market Size and Forecast, By Route Of Administration
        • 8.4.9.3. Market Size and Forecast, By Target
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.10.1. Market Size and Forecast, By Phase
        • 8.4.10.2. Market Size and Forecast, By Route Of Administration
        • 8.4.10.3. Market Size and Forecast, By Target
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.11.1. Market Size and Forecast, By Phase
        • 8.4.11.2. Market Size and Forecast, By Route Of Administration
        • 8.4.11.3. Market Size and Forecast, By Target
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.12.1. Market Size and Forecast, By Phase
        • 8.4.12.2. Market Size and Forecast, By Route Of Administration
        • 8.4.12.3. Market Size and Forecast, By Target
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.13.1. Market Size and Forecast, By Phase
        • 8.4.13.2. Market Size and Forecast, By Route Of Administration
        • 8.4.13.3. Market Size and Forecast, By Target
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.14.1. Market Size and Forecast, By Phase
        • 8.4.14.2. Market Size and Forecast, By Route Of Administration
        • 8.4.14.3. Market Size and Forecast, By Target
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.4.15.1. Market Size and Forecast, By Phase
        • 8.4.15.2. Market Size and Forecast, By Route Of Administration
        • 8.4.15.3. Market Size and Forecast, By Target
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Phase

      • 8.5.3. Market Size and Forecast, By Route Of Administration

      • 8.5.4. Market Size and Forecast, By Target

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.5.7.1. Market Size and Forecast, By Phase
        • 8.5.7.2. Market Size and Forecast, By Route Of Administration
        • 8.5.7.3. Market Size and Forecast, By Target
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.5.8.1. Market Size and Forecast, By Phase
        • 8.5.8.2. Market Size and Forecast, By Route Of Administration
        • 8.5.8.3. Market Size and Forecast, By Target
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.5.9.1. Market Size and Forecast, By Phase
        • 8.5.9.2. Market Size and Forecast, By Route Of Administration
        • 8.5.9.3. Market Size and Forecast, By Target
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.5.10.1. Market Size and Forecast, By Phase
        • 8.5.10.2. Market Size and Forecast, By Route Of Administration
        • 8.5.10.3. Market Size and Forecast, By Target
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.5.11.1. Market Size and Forecast, By Phase
        • 8.5.11.2. Market Size and Forecast, By Route Of Administration
        • 8.5.11.3. Market Size and Forecast, By Target
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Estrogen Receptor-positive Breast Cancer Pipeline Market

        • 8.5.12.1. Market Size and Forecast, By Phase
        • 8.5.12.2. Market Size and Forecast, By Route Of Administration
        • 8.5.12.3. Market Size and Forecast, By Target
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Novartis AG

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Genentech, Inc.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. GlaxoSmithKline Plc

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Mylan Pharmaceuticals Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Teva Pharmaceuticals USA, Inc.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. AstraZeneca

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Apotex Corp.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Breckenridge Pharmaceutical, Inc.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Pfizer Inc.

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Alvogen.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PRE-CLINICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHASE 1, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHASE 2, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHASE 3, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR SUBCUTANEOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHOSPHATIDYLINOSITOL-3-KINASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR CYCLIN-DEPENDENT KINASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR HISTONE DEACETYLASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. U.S. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 28. U.S. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. CANADA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. CANADA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 32. CANADA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. ITALY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 51. ITALY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. ITALY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 53. ITALY ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. UK ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 59. UK ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. UK ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 61. UK ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 63. RUSSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. CHINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. CHINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 78. CHINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. INDIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 84. INDIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 85. INDIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 86. INDIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 96. THAILAND ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 100. MALAYSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 104. INDONESIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 117. BRAZIL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 121. SOUTH AFRICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 125. SAUDI ARABIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 128. UAE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 129. UAE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 130. UAE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 131. UAE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 133. ARGENTINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY PHASE, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY TARGET, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 140. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 141. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 142. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 143. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 144. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. GENENTECH, INC.: KEY EXECUTIVES
  • TABLE 146. GENENTECH, INC.: COMPANY SNAPSHOT
  • TABLE 147. GENENTECH, INC.: OPERATING SEGMENTS
  • TABLE 148. GENENTECH, INC.: PRODUCT PORTFOLIO
  • TABLE 149. GENENTECH, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 151. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 152. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 153. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 154. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. MYLAN PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 156. MYLAN PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 157. MYLAN PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 158. MYLAN PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 159. MYLAN PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. TEVA PHARMACEUTICALS USA, INC.: KEY EXECUTIVES
  • TABLE 161. TEVA PHARMACEUTICALS USA, INC.: COMPANY SNAPSHOT
  • TABLE 162. TEVA PHARMACEUTICALS USA, INC.: OPERATING SEGMENTS
  • TABLE 163. TEVA PHARMACEUTICALS USA, INC.: PRODUCT PORTFOLIO
  • TABLE 164. TEVA PHARMACEUTICALS USA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 165. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 166. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 167. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 168. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 169. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 170. APOTEX CORP.: KEY EXECUTIVES
  • TABLE 171. APOTEX CORP.: COMPANY SNAPSHOT
  • TABLE 172. APOTEX CORP.: OPERATING SEGMENTS
  • TABLE 173. APOTEX CORP.: PRODUCT PORTFOLIO
  • TABLE 174. APOTEX CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 175. BRECKENRIDGE PHARMACEUTICAL, INC.: KEY EXECUTIVES
  • TABLE 176. BRECKENRIDGE PHARMACEUTICAL, INC.: COMPANY SNAPSHOT
  • TABLE 177. BRECKENRIDGE PHARMACEUTICAL, INC.: OPERATING SEGMENTS
  • TABLE 178. BRECKENRIDGE PHARMACEUTICAL, INC.: PRODUCT PORTFOLIO
  • TABLE 179. BRECKENRIDGE PHARMACEUTICAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 180. PFIZER INC.: KEY EXECUTIVES
  • TABLE 181. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 182. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 183. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 184. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 185. ALVOGEN.: KEY EXECUTIVES
  • TABLE 186. ALVOGEN.: COMPANY SNAPSHOT
  • TABLE 187. ALVOGEN.: OPERATING SEGMENTS
  • TABLE 188. ALVOGEN.: PRODUCT PORTFOLIO
  • TABLE 189. ALVOGEN.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET
  • FIGURE 3. SEGMENTATION ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET
  • FIGURE 11. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET SEGMENTATION, BY BY PHASE
  • FIGURE 12. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PRE-CLINICAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHASE 1, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHASE 2, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHASE 3, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 17. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR INTRAVENOUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR SUBCUTANEOUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET SEGMENTATION, BY BY TARGET
  • FIGURE 21. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR PHOSPHATIDYLINOSITOL-3-KINASE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR CYCLIN-DEPENDENT KINASE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR HISTONE DEACETYLASE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 26. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER PIPELINE MARKET
  • FIGURE 35. Top player positioning, 2022
  • FIGURE 36. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. GENENTECH, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. GENENTECH, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. GENENTECH, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. MYLAN PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. MYLAN PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. MYLAN PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. TEVA PHARMACEUTICALS USA, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. TEVA PHARMACEUTICALS USA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. TEVA PHARMACEUTICALS USA, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. APOTEX CORP.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. APOTEX CORP.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. APOTEX CORP.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. BRECKENRIDGE PHARMACEUTICAL, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. BRECKENRIDGE PHARMACEUTICAL, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. BRECKENRIDGE PHARMACEUTICAL, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. ALVOGEN.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. ALVOGEN.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. ALVOGEN.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Estrogen Receptor-positive Breast Cancer Pipeline Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers